Smartphone Apps for Patients With Hematologic Malignancies: Systematic Review and Evaluation of Content.

Introduction

Hematological malignancies (HMs) are a heterogeneous group of cancers that affect hematopoietic and lymphoid tissue. These disorders constitute 6.8% of all cancers, representing a significant cause of morbidity and mortality [ 1 ]. In the past decade, an increased incidence rate of HMs has been described [ 2 , 3 ], possibly due to a growth in life expectancy and the aging of the population [ 4 ].

HMs are frequently aggressive and require urgent, lengthy, and burdensome treatment. The complexity of HM treatments could reduce patient adherence and increase the risk of potential drug-drug interactions and adverse events [ 5 - 10 ]. Furthermore, patients with HMs and, specifically, patients with lymphoma and myeloma often experience psychological despair and poor quality of life throughout their illness course [ 11 - 13 ]. Although HM treatments add a burden to various aspects of a patient’s life, the wide range of treatments now available has significantly improved the management of these patients, often transforming HMs into chronic diseases with long-term survival [ 14 , 15 ].

The chronification of HMs in the digital era may lead patients to seek their current unmet needs through internet-based health care, mobile health (mHealth), and, specifically, smartphone apps. An increase in mHealth use is a likely scenario, since the use of smartphones is growing, with estimates indicating that 77.6% of Europeans own a smartphone [ 16 ]. In this context, health apps designed for patients with HMs could serve as additional tools for telemedicine, patient education and life coaching, medication adherence, communication, and social media connections [ 17 - 19 ].

As the number of health-related apps has increased rapidly in the last decade, there is an increasing need for research to assess the quality of eHealth tools and identify patients’ unmet needs.

This study aimed to identify apps that are accessible from Spain and are designed for patients diagnosed with HMs, analyze their characteristics, and evaluate their quality with the Mobile Application Rating Scale (MARS) [ 20 ].

Methods

Search Strategy

A systematic search of apps that were aimed at patients diagnosed with HMs, accessed from a Spain IP address, and were available on the iOS (App Store) and Android (Google Play) platforms was conducted from November 10, 2021, to November 25, 2021. The search was carried out following the PRISMA (Preferred Reporting Items for a Systematic Review and Meta-analysis) guidelines [ 21 ].

The search terms used were “hematology,” “blood cancer,” “leukemia,” “lymphoma,” “myeloma,” and their equivalents in the Spanish language—“hematología,” “cáncer de Sangre,” “leucemia,” “linfoma,” and “mieloma,” respectively.

The inclusion criteria used for selection were apps available in English or Spanish that were targeted at patients with HMs and included general information about HMs. The exclusion criteria used were apps that included inappropriate content (including horoscopes and astrology, among others), apps exclusively for fundraising for HMs that did not provide functions or tools designed for their use, or apps with nonfunctional links. The apps analyzed had to comply with all inclusion criteria to be included in the data extraction phase.

The names and descriptions of the apps from the search on Google Play and the App Store were selected against a priori selection criteria. The apps that met the inclusion criteria were downloaded for further screening using an Mi 9 Lite smartphone (Android version 10, Xiaomi Inc) for Google Play apps. For the apps downloaded from the App Store, an iPad Pro 2020 (Apple Inc) running iPadOS 15.1 was used. For apps duplicated across stores, the iOS app was evaluated because of the lower number of apps in the App Store compared with those in Google Play.

Data Extraction

Data were obtained from the App Store and Google Play online app descriptions (app characteristics and the narrative text) by 2 independent researchers. Data were extracted and entered into a structured Excel database (Microsoft Corp).

The variables collected for each app were the name, developer/owner name, type of developer/owner (commercial, scientific society, patient association), platform (Android or iOS), language (English or Spanish), app store category (eg, education, health and fitness, medicine), cost (€), date of publication (year), date of the last update (year), app file size (MB), app version, participation of health care professionals in the design and development of the app (yes/no), and HM targeted (eg, acute lymphocytic leukemia, multiple myeloma, Hodgkin lymphoma).

The participation of health care professionals was considered when specified in the app description or when the app was developed by a health organization (eg, a scientific society or a hospital). The purposes of the apps were classified into the following categories: assessment (eg, providing clinical scales, classifying adverse event severity, or interpreting laboratory findings), general information (eg, information about HMs, medications, or adverse events), the monitoring of clinical parameters (eg, register of laboratory parameters or symptoms), register of patient activities (eg, calendars for patients to add appointments and treatment administration), and contact with health care professionals or other patients.

A descriptive analysis was developed with continuous and discrete variables presented as mean and standard deviation and frequency and percentage, respectively. The means of continuous variables were compared using a t test. Results with a P value of <.05 were considered statistically significant. The generated data were analyzed using SPSS (version 26.0, IBM Corp).

App Quality Evaluation

To evaluate app quality, the MARS tool was used [ 20 ]. The MARS is a validated system to assess health apps that has been described as the most comprehensive for evaluating technical information and capabilities of apps [ 20 , 22 , 23 ]. This tool has been widely used to evaluate health apps designed for many diseases [ 24 - 30 ].

The MARS comprises 23 items across 5 subscales:

Engagement: evaluates the entertainment, interest, customization, interactivity, and adequacy of the target group

Functionality: assesses the performance, ease of use, navigation, and gestural design of the app

Aesthetics: examines the layout, graphics, and visual appeal of the app

Information: assesses the accuracy of the description, establishment of goals, quality and quantity of information, visual information, credibility of the source, and evidence-based development of the app

Subjective quality: determines willingness to recommend app, times app will be used, willingness to pay, and overall rating of app

Each criterion is evaluated from 1 to 5 (1=inadequate; 2=poor; 3=acceptable; 4=good; 5=excellent). A mean score of the 5 subscales is calculated to describe overall quality.

Before the app search was carried out, reviewers read and became acquainted with the MARS tool. All authors then discussed each rating criteria to achieve a consensus on how to apply them. The first app included was evaluated concurrently by all reviewers to ensure a common understanding and application of the MARS tool. The apps included were independently assessed by 2 reviewers, whose scores were then compared, and a final MARS score was agreed upon. A third reviewer was invited to resolve discrepancies if a consensus on the final MARS score was not reached.

In order to quantify the subjectivity degree of the reviewers’ evaluations, the interrater reliability of the quality scores between the independent evaluations was calculated using the intraclass correlation coefficient (ICC) for a 2-way random effects model.

Results

Overview

The titles, descriptions, and screenshots of 1390 apps were screened in a pair-review fashion. Overall, 18 apps met the inclusion criteria for a comprehensive evaluation with the MARS tool ( Figure 1 ).

App Characteristics

Table 1 displays the general features of the apps. Regarding the apps available on the platforms searched, 7 were available on Google Play (Android), 5 were available on the App Store (iOS), and 6 were available on both platforms. The apps were categorized in different sections in their respective platforms, as follows: medicine (11), health and well-being (4), education (1), news (1), and books and reference works (1). All apps evaluated were free. The average file size of the apps was 27.2 (SD 25.3) MB.

Table 2 displays apps’ purposes and health care professional involvement in their design. All 7 apps with a unique purpose were designed to provide information about HMs and their management. Eleven apps had multiple purposes, the most frequent being providing information and monitoring symptoms and clinical parameters. Overall, 9 of the apps were developed with the participation of health care professionals, 6 were owned and supported by scientific societies, and 3 were developed with the participation of physicians or nurses. None of the included apps reported clinical efficacy through clinical trials in patients with HMs.

App Quality Assessment

Tables 3 and 4 display the MARS subscales scores for the individual apps. The scores in the functionality section were similar between the apps. The movements between menus and screens were fast and satisfactory for most apps. The most remarkable differences were found in the information and aesthetics sections, for which only 67% (12/18) and 61% (11/18) of the apps showed acceptable scores (>3), respectively. None of the apps were tested in clinical trials.

The mean MARS score was 3.1 (SD 1.0), considering this value as acceptable. Table 5 contains the overall quality scores. For 5 apps, the mean MARS score was >4, meaning these apps were of good quality. On the other hand, 7 apps received a mean score of <3 and were classified as poor-quality apps.

iOS apps obtained better MARS scores when compared to apps for Android (+1.0) points when comparing apps based on their platforms. This difference was statistically significant for the mean MARS score ( P =.003) and for all 5 domains: engagement (+1.0; P =.001), functionality (+0.6, P =.05), aesthetics (+1.1, P =.01), information (+1.0, P =.01), and subjective evaluation (+1.1, P =.002). For apps available on both platforms, the MARS mean scores were higher than those for apps only available on one of the platforms (+0.6, P =.19). The aesthetic domain score was statistically superior for apps available on both platforms (+1.2, P =.04). The participation of health care professionals had a positive impact on the appraisals of the apps (+0.6 points), but no statistically significant differences were found ( P =.22).

For the overall MARS ratings, the ICC was 0.94 (95% CI 0.75-0.98), confirming excellent interrater reliability. For the engagement, functionality, aesthetics, information, and subjective domains, the ICCs were 0.84, 0.86, 0.94, 0.95, and 0.93, respectively.

Discussion

Principal Findings

Health apps have the potential to become a standard of care for chronic patients. Apps have been associated with positive patient outcomes such as improved adherence to medication and quality of life and decreased use of health care–related resources [ 31 ]. Therefore, health apps may offer valuable tools for patients with HMs in a health care context [ 17 , 32 - 34 ].

This systematic review highlighted the limited number of apps available for patients with HMs. The number of apps identified in this study was significantly lower than previously published reviews on COVID-19, neoplasms, and specific types of cancer such as breast cancer [ 35 - 37 ]. The apps were developed for a narrow range of diseases that HMs encompass. Currently, patients with acute myeloid leukemia or non-Hodgkin lymphoma do not have access to eHealth tools in the main app stores that specifically target these diseases. In addition, there is a lack of apps specifically designed for children, regardless of them being a significant population of patients with HMs who have distinct needs [ 38 , 39 ].

The low number of apps found in this review may be due to several reasons. First, HMs are relatively rare; according to the Global Cancer Observatory, HMs account for an estimated 6.8% of all cancers worldwide [ 1 ]. Similarly, systematic searches for diseases with low prevalence tend to find few apps directed to patients [ 1 , 24 , 40 , 41 ]. Second, strict exclusion criteria were applied for app selection—specifically, the exclusion of apps aimed at health care professionals, which may encompass half of the health apps [ 42 ]. Third, HMs often affect older patients, an age group for which developers may often not design eHealth tools [ 43 , 44 ]. Older age has been associated with a lack of interest in eHealth and smartphones [ 45 , 46 ]. This population also faces additional barriers to using eHealth, such as physical disability and technology inexperience [ 47 , 48 ].

All apps included for evaluation were designed to serve as an information source or monitoring tool for medications and symptoms. The information was not frequently reviewed and updated, as only half of the HM apps (9/18, 50%) were updated during 2021. The management of HMs is in continuous change, often requiring guidelines and recommendations to be updated with frequency, often yearly. As an illustration of this constant evolution, the European Medicines Agency has recommended for approval an average of 5 drugs for HMs per year [ 49 ]. The growing arsenal of new treatments highlights the importance of regularly updating apps according to changes in guidelines and recommendations, as the management of HMs is a complex field of constant change [ 50 ].

Among the few apps that complied with the inclusion criteria for this study, the overall quality was acceptable. The highest rated subscale on the MARS was functionality due to app efficiency and ease of use. On the other hand, the engagement subscale was the worst evaluated, specifically the customization and interactivity items. Poor results in the engagement domain could mean that even if quality apps include valuable tools, patients will use them for limited periods. Furthermore, the customization of app interactions by setting personalized reminders is perceived as highly beneficial by patients with HMs [ 51 - 53 ]. Finally, the credibility item was poorly evaluated, as the existence of commercial interests or the source’s legitimacy could not be verified.

Currently, there is a lack of high-quality evidence on the eHealth needs of patients with HMs. Surveys about communication technologies conducted on hematology and oncology patients found that mobile phones were the most frequently used device to search for health-related information. Patients were highly interested in staying informed about health issues, disease prevention, healthy lifestyles, and general information about the disease [ 31 , 54 ]. Patients seem to be interested in eHealth helping with practical issues, such as appointment management, the provision of advice on disease and symptom management, and direct communication with health care professionals in addition to providing information. Patients were less interested in features that can add additional burdens to their daily activities, such as recording and monitoring medication, symptoms, and adverse events [ 31 ]. Patients with HMs also desire the creation of communication channels that allow health care professionals to answer their concerns rapidly [ 31 ]. A scoping review of virtual care in patients with HMs described high patient satisfaction with telemedicine interventions that allowed clinicians and nurses to communicate via phone calls or videoconferencing [ 33 ].

The 18 apps that were designed for patients with HMs and were evaluated in this review did not fulfill the previously described preferences. Although 17 apps provided information about the disease, most of the information did not focus on disease prevention, symptom management, or healthy lifestyles. In addition, direct communication with health care professionals for Spanish patients was not possible, and the management of medical appointments was not an included feature. Further research on the virtual care needs of patients with HMs is warranted; surveys and validated questionnaires explicitly designed for patients with HMs are needed to gain knowledge of the unmet needs of these patients. Understanding patient preferences through a continuous user-centered design is essential for the success of mHealth for patients with HMs [ 50 , 55 ]. The differences found between features included in apps and the preferences of patients with HMs highlight the apparent necessity of their participation in the design of health-related apps. The inclusion of health care professionals may not be sufficient to adequately provide quality apps that cover patient needs, as there is a divide between the expectations and needs of patients and those identified by health care professionals [ 56 , 57 ].

Among the stakeholders involved in the management of HMs, the participation of health care professionals in the development of mHealth apps is frequently described as a critical factor related to their general quality and, specifically, the quality of the information provided [ 24 , 25 , 58 ]. A systematic review that evaluated expert participation and adherence to medical evidence in mHealth apps showed that the lack of participation of health care professionals and inclusion of evidence-based information were persistent characteristics of the available health apps [ 58 ]. However, even when these factors are potentially related, expert involvement in the design does not guarantee adherence to evidence-based content [ 58 , 59 ]. In this review, half of the apps (9/18, 50%) targeting patients with HMs included the participation of health care professionals in the development phase. Nevertheless, we did not find statistically significant differences in the quality scores based on this participation. Furthermore, a cross-sectional survey of oncology and hematology patients found that more than 80% of patients would use an app if a health professional recommended it [ 60 ]. These data suggest that health care professionals may also play a crucial role in high-quality apps reaching patients with HMs.

Due to the complex nature of HMs, which often require highly complex and burdensome therapeutic protocols, we could presume that patients would benefit from additional tools that help manage different aspects of the disease. However, the role of apps in the care of patients with HMs is uncertain; a review exploring the research on eHealth intervention in HMs found that few trials were designed exclusively for patients with HMs. These studies generally included mixed cancer groups composed of a small sample of hematology patients; moreover, the principal study results were not presented separately [ 34 ]. Similarly, among the 18 apps evaluated in this review, none assessed the clinical impact of the intervention through clinical trials; this finding is common among studies that evaluate health apps, with authors often stating the need for studies that assess the efficacy of health apps [ 23 - 25 , 37 , 61 , 62 ]. Additional randomized controlled trials testing the efficacy of apps are warranted before implementing this technology for managing HMs, as eHealth may also increase the burden of treatment on vulnerable patients [ 63 , 64 ].

Recommendations and Future Research for HM App Development

Current and future apps for patients with HMs should focus on improving the lowest rated subscales of the MARS scale: engagement and aesthetics. Specifically, improvements are needed in the interactivity, customization, and entertainment features, as well as in graphical design and visual appeal. Further refinement of the information provided may be needed in order to deliver updated evidence-based information adapted to the necessities and preferences of patients with HMs. In this context, HM apps should be developed through a user-centered, collaborative design process with the participation of all stakeholders involved. The participation of health care professionals can increase the credibility of apps and trustworthiness of sources [ 24 , 25 , 58 ]. Furthermore, the participation of patients with HMs is essential for developing apps that fulfill their unmet needs, increasing their usability [ 56 , 57 ]. App developers and stakeholders should work to include apps in specialized and primary care assistance circuits by adding functions that facilitate the access of patients with HMs to health assistance through the management of appointments and direct communication with health care professionals [ 31 , 54 ]. Regular updates of app contents should be performed to incorporate information that is consistent with recently generated evidence.

Future research in the field of HM apps should focus on gaining knowledge regarding the eHealth needs of patients with HMs, conducting surveys that investigate the changing needs of specific groups of patients with HMs, measuring the existence of health app safety concerns, and generating evidence-based data on the effectiveness of eHealth interventions through apps in patients with HMs.

Limitations

This systematic review has several limitations. First, the reviewers assigned a score for each category using brief descriptions of what makes an excellent, regular, or mediocre app. Thus, there was a degree of subjectivity when evaluating apps using the MARS [ 21 , 22 ]. However, the multiple reviewer design of this study may narrow the impact of this limitation because of the high degree of interreviewer agreement observed. Second, despite the MARS being a validated tool that is widely used to assess the quality of apps for many diseases [ 23 - 29 ], it does not consider aspects such as privacy, security, and the frequency of updates to apps, which have been considered aspects of particular relevance when evaluating the quality of health software [ 65 ]. Third, as health care professionals, the authors evaluated apps aimed at patients; this has limitations, as we may not fully comprehend their needs and preferences [ 56 , 57 ]. Fourth, the search was limited to 2 app platforms: Google Play and the App Store. Although these platforms encompass the vast majority of apps available on the market [ 66 ], several platforms (Windows Phone, Blackberry Market, etc) were not included in this review due to the lack of availability of devices for performing the search among the reviewers. Therefore, the possibility exists that some apps dedicated to HMs were missed.

Conclusion

The potential for eHealth to improve the care of patients with HMs exists. However, current apps need further refinement in order to provide evidence-based valuable information, keep users engaged, and provide a visually appealing interface. Moreover, there is a need to generate evidence on the efficacy of eHealth interventions in patients with HMs.

Future eHealth tools for patients with HMs should consider including all stakeholders in the design phase. Notably, the participation of patients in this phase will serve to design and implement tools according to their currently unmet needs.

The authors are immensely grateful to Dominica Melgar Carrascal for her valuable ideas and insight into hematological malignancy app potential and limitations from the perspective of patients with hematological malignancies.

Authors' Contributions: NBG and HRR conceived the study. NBG, HRR, and MFG collected the data and wrote the manuscript. NBG, HRR, MFG, and LAKM contributed to the interpretation of the results and reviewed the paper. All authors have reviewed and approved the last version of the manuscript.

Conflicts of Interest: None declared.

Abbreviations

hematological malignancy

intraclass correlation coefficient

Mobile Application Rating Scale

mobile health

Preferred Reporting Items for a Systematic Review and Meta-analysis

1 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 02 04 209 249 10.3322/caac.21660 10.3322/caac.21660 33538338 33538338

2 Global Burden of Disease Cancer Collaboration Fitzmaurice C Akinyemiju TF Al Lami FH Alam T Alizadeh-Navaei R Allen C Alsharif U Alvis-Guzman N Amini E Anderson BO Aremu O Artaman A Asgedom SW Assadi R Atey TM Avila-Burgos L Awasthi A Ba Saleem HO Barac A Bennett JR Bensenor IM Bhakta N Brenner H Cahuana-Hurtado L Castañeda-Orjuela CA Catalá-López F Choi JJ Christopher DJ Chung S Curado MP Dandona L Dandona R das Neves J Dey S Dharmaratne SD Doku DT Driscoll TR Dubey M Ebrahimi H Edessa D El-Khatib Z Endries AY Fischer F Force LM Foreman KJ Gebrehiwot SW Gopalani SV Grosso G Gupta R Gyawali B Hamadeh RR Hamidi S Harvey J Hassen HY Hay RJ Hay SI Heibati B Hiluf MK Horita N Hosgood HD Ilesanmi OS Innos K Islami F Jakovljevic MB Johnson SC Jonas JB Kasaeian A Kassa TD Khader YS Khan EA Khan G Khang Y Khosravi MH Khubchandani J Kopec JA Kumar GA Kutz M Lad DP Lafranconi A Lan Q Legesse Y Leigh J Linn S Lunevicius R Majeed A Malekzadeh R Malta DC Mantovani LG McMahon BJ Meier T Melaku YA Melku M Memiah P Mendoza W Meretoja TJ Mezgebe HB Miller TR Mohammed S Mokdad AH Moosazadeh M Moraga P Mousavi SM Nangia V Nguyen CT Nong VM Ogbo FA Olagunju AT Pa M Park E Patel T Pereira DM Pishgar F Postma MJ Pourmalek F Qorbani M Rafay A Rawaf S Rawaf DL Roshandel G Safiri S Salimzadeh H Sanabria JR Santric Milicevic MM Sartorius B Satpathy M Sepanlou SG Shackelford KA Shaikh MA Sharif-Alhoseini M She J Shin M Shiue I Shrime MG Sinke AH Sisay M Sligar A Sufiyan MB Sykes BL Tabarés-Seisdedos R Tessema GA Topor-Madry R Tran TT Tran BX Ukwaja KN Vlassov VV Vollset SE Weiderpass E Williams HC Yimer NB Yonemoto N Younis MZ Murray CJL Naghavi M Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study JAMA Oncol 2018 11 01 4 11 1553 1568 10.1001/jamaoncol.2018.2706 29860482 2683251 29860482 PMC6248091

3 Cowan AJ Allen C Barac A Basaleem H Bensenor I Curado MP Foreman K Gupta R Harvey J Hosgood HD Jakovljevic M Khader Y Linn S Lad D Mantovani L Nong VM Mokdad A Naghavi M Postma M Roshandel G Shackelford K Sisay M Nguyen CT Tran TT Xuan BT Ukwaja KN Vollset SE Weiderpass E Libby EN Fitzmaurice C Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016 JAMA Oncol 2018 09 01 4 9 1221 1227 10.1001/jamaoncol.2018.2128 29800065 2681640 29800065 PMC6143021

4 GBD 2017 Mortality Collaborators Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 2018 11 10 392 10159 1684 1735 10.1016/S0140-6736(18)31891-9 30496102 S0140-6736(18)31891-9 30496102 PMC6227504

5 Umıt EG Baysal M Bas V Asker I Kırkızlar O Demır AM Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy J Oncol Pharm Pract 2020 01 26 1 43 50 10.1177/1078155219835303 30890065 30890065

6 Leger DY Moreau S Signol N Fargeas J Picat M Penot A Abraham J Laroche M Bordessoule D Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: observational single-center study of 122 patients J Geriatr Oncol 2018 01 9 1 60 67 10.1016/j.jgo.2017.07.015 28851511 S1879-4068(17)30145-5 28851511

7 Dhakal P Lyden E Muir KE Al-Kadhimi ZS Koll T Maness LJ Gundabolu K Bhatt VR Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia Leuk Lymphoma 2020 07 61 7 1702 1708 10.1080/10428194.2020.1737687 32157936 32157936 PMC9393046

8 Mian H Fiala M Wildes TM Adherence to lenalidomide in older adults with newly diagnosed multiple myeloma Clin Lymphoma Myeloma Leuk 2020 02 20 2 98 104 10.1016/j.clml.2019.09.618 31843543 S2152-2650(19)32005-1 31843543 PMC7564009

9 Kristjánsdóttir ER Toksvang LN Schmiegelow K Rank CU Prevalence of non-adherence and non-compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival Eur J Haematol 2022 02 108 2 109 117 10.1111/ejh.13711 34562333 34562333

10 Mancini J Simeoni M Parola N Clement A Vey N Sirvent N Michel G Auquier P Adherence to leukemia maintenance therapy: a comparative study among children, adolescents, and adults Pediatr Hematol Oncol 2012 08 29 5 428 439 10.3109/08880018.2012.693150 22712832 22712832

11 Hall A Lynagh M Bryant J Sanson-Fisher R Supportive care needs of hematological cancer survivors: a critical review of the literature Crit Rev Oncol Hematol 2013 10 88 1 102 116 10.1016/j.critrevonc.2013.03.008 23582686 S1040-8428(13)00068-1 23582686

12 Allart-Vorelli P Porro B Baguet F Michel A Cousson-Gélie F Haematological cancer and quality of life: a systematic literature review Blood Cancer J 2015 04 24 5 e305 10.1038/bcj.2015.29 10.1038/bcj.2015.29 25909835 bcj201529 25909835 PMC4450328

13 Allart P Soubeyran P Cousson-Gélie F Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature Psychooncology 2013 02 22 2 241 249 10.1002/pon.3026 22287503 22287503

14 Phillips JL Currow DC Cancer as a chronic disease Collegian 2010 17 2 47 50 10.1016/j.colegn.2010.04.007 20738055 20738055

15 Global Burden of Disease 2019 Cancer Collaboration Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019 JAMA Oncol 2022 8 3 420 444 10.1001/jamaoncol.2021.6987 34967848 34967848 PMC8719276

16 Smartphone market in Europe: statistics and facts Statista 2022-06-07 https://www.statista.com/topics/3341/smartphone-market-in-europe/

17 Jagannath S Mikhael J Nadeem O Raje N Digital health for patients with multiple myeloma: an unmet need JCO Clin Cancer Inform 2021 10 5 1096 1105 10.1200/CCI.20.00145 34735265 34735265

18 Binder AF Handley NR Wilde L Palmisiano N Lopez AM Treating hematologic malignancies during a pandemic: utilizing telehealth and digital technology to optimize care Front Oncol 2020 6 26 10 1183 10.3389/fonc.2020.01183 10.3389/fonc.2020.01183 32676459 32676459 PMC7333768

19 Psihogios AM Li Y Ahmed A Huang J Kersun LS Schwartz LA Barakat LP Daily text message assessments of 6-mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: a pilot study Pediatr Blood Cancer 2021 02 68 2 e28767 10.1002/pbc.28767 33073479 33073479 PMC10313157

20 Stoyanov SR Hides L Kavanagh DJ Zelenko O Tjondronegoro D Mani M Mobile app rating scale: a new tool for assessing the quality of health mobile apps JMIR Mhealth Uhealth 2015 3 1 e27 10.2196/mhealth.3422 25760773 v3i1e27 25760773 PMC4376132

21 Moher D Shamseer L Clarke M Ghersi D Liberati A Petticrew M Shekelle P Stewart LA PRISMA- P Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Syst Rev 2015 01 4 1 10.1186/2046-4053-4-1 25554246 2046-4053-4-1 25554246 PMC4320440

22 Dawson RM Felder TM Donevant SB McDonnell KK Card EB King CC Heiney SP What makes a good health 'app'? Identifying the strengths and limitations of existing mobile application evaluation tools Nurs Inq 2020 04 27 2 e12333 10.1111/nin.12333 31854055 31854055 PMC7181198

23 Terhorst Y Philippi P Sander LB Schultchen D Paganini S Bardus M Santo K Knitza J Machado GC Schoeppe S Bauereiß N Portenhauser A Domhardt M Walter B Krusche M Baumeister H Messner E Validation of the Mobile Application Rating Scale (MARS) PLoS One 2020 15 11 e0241480 10.1371/journal.pone.0241480 33137123 PONE-D-20-14930 33137123 PMC7605637

24 Kwan YH Ong WJ Xiong M Leung YY Phang JK Wang CTM Fong W Evaluation of mobile apps targeted at patients with spondyloarthritis for disease monitoring: systematic app search JMIR Mhealth Uhealth 2019 10 28 7 10 e14753 10.2196/14753 31661080 v7i10e14753 31661080 PMC6913729

25 Amor-García Collado-Borrell R Escudero-Vilaplana V Melgarejo-Ortuño A Herranz-Alonso A Arranz Arija Sanjurjo-Sáez M Assessing apps for patients with genitourinary tumors using the Mobile Application Rating Scale (MARS): systematic search in app stores and content analysis JMIR Mhealth Uhealth 2020 07 23 8 7 e17609 10.2196/17609 32706737 v8i7e17609 32706737 PMC7413276

26 Kim BY Sharafoddini A Tran N Wen EY Lee J Consumer mobile apps for potential drug-drug interaction check: systematic review and content analysis using the Mobile App Rating Scale (MARS) JMIR Mhealth Uhealth 2018 03 28 6 3 e74 10.2196/mhealth.8613 29592848 v6i3e74 29592848 PMC5895923

27 Devan H Farmery D Peebles L Grainger R Evaluation of self-management support functions in apps for people with persistent pain: systematic review JMIR Mhealth Uhealth 2019 02 12 7 2 e13080 10.2196/13080 30747715 v7i2e13080 30747715 PMC6390192

28 Gong E Zhang Z Jin X Liu Y Zhong L Wu Y Zhong X Yan LL Oldenburg B Quality, functionality, and features of chinese mobile apps for diabetes self-management: systematic search and evaluation of mobile apps JMIR Mhealth Uhealth 2020 04 07 8 4 e14836 10.2196/14836 32255432 v8i4e14836 32255432 PMC7175187

29 Escoffery C McGee R Bidwell J Sims C Thropp EK Frazier C Mynatt ED A review of mobile apps for epilepsy self-management Epilepsy Behav 2018 04 81 62 69 10.1016/j.yebeh.2017.12.010 29494935 S1525-5050(17)30728-X 29494935

30 Masterson CRM Maurer MS Reading M Hiraldo G Hickey KT Iribarren S Review and analysis of existing mobile phone apps to support heart failure symptom monitoring and self-care management using the Mobile Application Rating Scale (MARS) JMIR Mhealth Uhealth 2016 06 14 4 2 e74 10.2196/mhealth.5882 27302310 v4i2e74 27302310 PMC4925936

31 Collado-Borrell R Escudero-Vilaplana V Narrillos-Moraza Á Patient-reported outcomes y aplicaciones móviles. Revisión de su impacto en los resultados en salud de los pacientes Farmacia Hospitalaria 2022 9 10.7399/fh.11830 36183211

32 Tsatsou I Konstantinidis T Kalemikerakis I Adamakidou T Vlachou E Govina O Unmet supportive care needs of patients with hematological malignancies: a systematic review Asia Pac J Oncol Nurs 2021 8 1 5 17 10.4103/apjon.apjon_41_20 33426184 S2347-5625(21)00010-X 33426184 PMC7785074

33 Suleman A Vijenthira A Berlin A Prica A Rodin D The use of virtual care in patients with hematologic malignancies: a scoping review Curr Oncol 2022 02 07 29 2 892 900 10.3390/curroncol29020076 35200575 curroncol29020076 35200575 PMC8871074

34 Taylor S Bellhouse S Allsop M Radford J Yorke J The role of eHealth in the delivery of care for patients with hematological cancers: a systematic literature review Telemed J E Health 2020 09 26 9 1093 1105 10.1089/tmj.2019.0231 32208067 32208067

35 Collado-Borrell R Escudero-Vilaplana V Villanueva-Bueno C Herranz-Alonso A Sanjurjo-Saez M Features and functionalities of smartphone apps related to COVID-19: systematic search in app stores and content analysis J Med Internet Res 2020 08 25 22 8 e20334 10.2196/20334 32614777 v22i8e20334 32614777 PMC7479586

36 Adam R McMichael D Powell D Murchie P Publicly available apps for cancer survivors: a scoping review BMJ Open 2019 09 30 9 9 e032510 10.1136/bmjopen-2019-032510 31575584 bmjopen-2019-032510 PMC6773350 31575584

37 Mobasheri MH Johnston M King D Leff D Thiruchelvam P Darzi A Smartphone breast applications—what's the evidence? Breast 2014 10 23 5 683 689 10.1016/j.breast.2014.07.006 25153432 S0960-9776(14)00136-2 25153432

38 Hummelinck A Pollock K Parents' information needs about the treatment of their chronically ill child: a qualitative study Patient Educ Couns 2006 08 62 2 228 234 10.1016/j.pec.2005.07.006 16139981 S0738-3991(05)00227-2 16139981

39 Modi AC Pai AL Hommel KA Hood KK Cortina S Hilliard ME Guilfoyle SM Gray WN Drotar D Pediatric self-management: a framework for research, practice, and policy Pediatrics 2012 02 129 2 e473 e485 10.1542/peds.2011-1635 22218838 peds.2011-1635 22218838 PMC9923567

40 Owens OL Beer JM Reyes LI Thomas TL Systematic review of commercially available mobile phone applications for prostate cancer education Am J Mens Health 2019 13 1 1557988318816912 10.1177/1557988318816912 30526243 30526243 PMC6775560

41 Stolwijk C van Onna M Boonen A van Tubergen A Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis Arthritis Care Res (Hoboken) 2016 09 68 9 1320 1331 10.1002/acr.22831 10.1002/acr.22831 26713432 26713432

42 Cannon C Telehealth, mobile applications, and wearable devices are expanding cancer care beyond walls Semin Oncol Nurs 2018 05 34 2 118 125 10.1016/j.soncn.2018.03.002 29627143 S0749-2081(18)30015-9 29627143

43 Smith A Howell D Patmore R Jack A Roman E Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network Br J Cancer 2011 11 22 105 11 1684 1692 10.1038/bjc.2011.450 22045184 bjc2011450 22045184 PMC3242607

44 Tietsche de Moraes Hungria V Chiattone C Pavlovsky M Abenoza LM Agreda GP Armenta J Arrais C Avendaño Flores O Barroso F Basquiera AL Cao C Cugliari MS Enrico A Foggliatto LM Galvez KM Gomez D Gomez A de Iracema D Farias D Lopez L Mantilla WA Martínez D Mela MJ Miguel CE Ovilla R Palmer L Pavlovsky C Ramos C Remaggi G Santucci R Schusterschitz S Sossa CL Tuna-Aguilar E Vela J Santos T de la Mora O Machnicki G Fernandez M Barreyro P Epidemiology of hematologic malignancies in real-world settings: findings from the hemato-oncology latin america observational registry study J Glob Oncol 2019 11 5 1 19 10.1200/JGO.19.00025 31774711 PMC6882510 31774711

45 Heponiemi T Kaihlanen A Kouvonen A Leemann L Taipale S Gluschkoff K The role of age and digital competence on the use of online health and social care services: a cross-sectional population-based survey Digit Health 2022 8 20552076221074485 10.1177/20552076221074485 35111333 10.1177_20552076221074485 35111333 PMC8801649

46 Wilson J Heinsch M Betts D Booth D Kay-Lambkin F Barriers and facilitators to the use of e-health by older adults: a scoping review BMC Public Health 2021 08 17 21 1 1556 10.1186/s12889-021-11623-w 34399716 10.1186/s12889-021-11623-w 34399716 PMC8369710

47 Nieman CL Oh ES Connecting with older adults via telemedicine Ann Intern Med 2020 11 17 173 10 831 832 10.7326/M20-1322 32777187 32777187

48 Lam K Lu AD Shi Y Covinsky KE Assessing telemedicine unreadiness among older adults in the United States during the COVID-19 pandemic JAMA Intern Med 2020 10 01 180 10 1389 1391 10.1001/jamainternmed.2020.2671 32744593 2768772 32744593 PMC7400189

49 Medicine evaluation figures European Medicines Agency 2022-06-09 https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines/medicine-evaluation-figures

50 Finnes HD 2019-2020 drug updates in hematologic malignancies J Adv Pract Oncol 2021 04 12 3 279 283 10.6004/jadpro.2021.12.3.12 34084575 2021.12.3.12 34084575 PMC8087224

51 Wu Y Linder L Kanokvimankul P Fowler B Parsons B Macpherson C Johnson R Use of a smartphone application for prompting oral medication adherence among adolescents and young adults with cancer Oncol Nurs Forum 2018 01 01 45 1 69 76 10.1188/18.ONF.69-76 29251285 29251285 PMC5927589

52 Heneghan MB Hussain T Barrera L Cai SW Haugen M Morgan E Rossoff J Weinstein J Hijiya N Cella D Badawy SM Access to technology and preferences for an mhealth intervention to promote medication adherence in pediatric acute lymphoblastic leukemia: approach leveraging behavior change techniques J Med Internet Res 2021 02 18 23 2 e24893 10.2196/24893 33599621 v23i2e24893 33599621 PMC7932843

53 Pereira-Salgado A Westwood JA Russell L Ugalde A Ortlepp B Seymour JF Butow P Cavedon L Ong K Aranda S Breen S Kirsa S Dunlevie A Schofield P Mobile health intervention to increase oral cancer therapy adherence in patients with chronic myeloid leukemia (The REMIND System): clinical feasibility and acceptability assessment JMIR Mhealth Uhealth 2017 12 06 5 12 e184 10.2196/mhealth.8349 29212628 v5i12e184 29212628 PMC5738545

54 Raghunathan NJ Korenstein D Li QS Tonorezos ES Mao JJ Determinants of mobile technology use and smartphone application interest in cancer patients Cancer Med 2018 11 7 11 5812 5819 10.1002/cam4.1660 10.1002/cam4.1660 30280495 30280495 PMC6246952

55 Perski O Blandford A West R Michie S Conceptualising engagement with digital behaviour change interventions: a systematic review using principles from critical interpretive synthesis Transl Behav Med 2016 12 13 7 2 254 267 10.1007/s13142-016-0453-1 27966189 10.1007/s13142-016-0453-1 PMC5526809 27966189

56 Tarricone R Cucciniello M Armeni P Petracca F Desouza KC Hall LK Keefe D Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey JMIR Mhealth Uhealth 2019 09 06 7 9 e13584 10.2196/13584 31493318 v7i9e13584 31493318 PMC6754682

57 Nair SC Hassen WA Sreedharan J Qawasmeh K Ibrahim H Comparison of perceptions of unmet supportive care needs between cancer patients and their oncologists Support Care Cancer 2019 11 27 11 4229 4235 10.1007/s00520-019-04705-4 30847701 10.1007/s00520-019-04705-4 30847701

58 Subhi Y Bube SH Rolskov BS Skou TAS Konge L Expert involvement and adherence to medical evidence in medical mobile phone apps: a systematic review JMIR Mhealth Uhealth 2015 07 27 3 3 e79 10.2196/mhealth.4169 26215371 v3i3e79 26215371 PMC4705370

59 Haffey F Brady RRW Maxwell S A comparison of the reliability of smartphone apps for opioid conversion Drug Saf 2013 02 36 2 111 117 10.1007/s40264-013-0015-0 23322549 23322549

60 Collado-Borrell R Escudero-Vilaplana V Calles A Garcia-Martin E Marzal-Alfaro B Gonzalez-Haba E Herranz-Alonso A Sanjurjo-Saez M Oncology patient interest in the use of new technologies to manage their disease: cross-sectional survey J Med Internet Res 2018 10 23 20 10 e11006 10.2196/11006 30355554 v20i10e11006 30355554 PMC6318148

61 Free C Phillips G Watson L Galli L Felix L Edwards P Patel V Haines A The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis PLoS Med 2013 01 10 1 e1001363 10.1371/journal.pmed.1001363 23458994 PMEDICINE-D-12-00641 23458994 PMC3566926

62 Connor K Brady RRW de Beaux A Tulloh B Contemporary hernia smartphone applications (apps) Hernia 2014 08 18 4 557 561 10.1007/s10029-013-1130-7 23801277 23801277

63 Mair FS Montori VM May CR Digital transformation could increase the burden of treatment on patients BMJ 2021 11 25 375 n2909 10.1136/bmj.n2909 34824093 34824093

64 Mair FS May CR Thinking about the burden of treatment BMJ 2014 11 10 349 g6680 10.1136/bmj.g6680 25385748 25385748

65 Lewis TL Wyatt JC mHealth and mobile medical Apps: a framework to assess risk and promote safer use J Med Internet Res 2014 09 15 16 9 e210 10.2196/jmir.3133 25223398 v16i9e210 25223398 PMC4180335

66 Biggest app stores in the world Statista 2022-06-11 https://www.statista.com/statistics/276623/number-of-apps-available-in-leading-app-stores/